middle.news
Botanix Dismisses US Drug Pricing Impact Amid Trump Executive Order Proposal
2:45am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Botanix Dismisses US Drug Pricing Impact Amid Trump Executive Order Proposal
2:45am on Monday 2nd of June, 2025 AEST
Key Points
Botanix's Sofdra approved and marketed only in the USA
US executive order proposes 'most favored nation' drug pricing policy
Botanix's partner markets a different sofpironium formulation in Japan
No expected price reductions from overseas sales due to product exclusivity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Botanix Pharmaceuticals (ASX:BOT)
OPEN ARTICLE